TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00307736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT)
Description: Given on days 1-5 and 8-12
Study: NCT00423267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
Study: NCT03307395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middel Meningeal Artery Embolization
Description: Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
Study: NCT01599611

Intervention type: PROCEDURE
Intervention: Movement assessment battery for children - 2
Description: A standardised test developed to identify developmental difficulties in children.

Intervention type: PROCEDURE
Intervention: Movement assessment battery for children - 2
Description: A standardised test developed to identify developmental difficulties in children.
Study: NCT04630561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural Intervention Program
Description: Dynamic warmup program designed to target several areas of physical and mental wellbeing.
Study: NCT00198510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: 7.5 IU of Vitrase
Study: NCT03277755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 25 mg
Description: Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 25 mg
Description: Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV 75 mg
Description: Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV 75 mg
Description: Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study: NCT01739127

Intervention type: DRUG
Intervention: Aripiprazole
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

Intervention type: DRUG
Intervention: Risperidone/Quetiapine
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
Study: NCT00695305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilapladib
Description: 250 mg oral dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 18F Fluorodeoxylucose (FDG)-PET
Description: FDG-PET
Study: NCT04582084

Intervention type: DRUG
Intervention: Etanercept
Description: Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
Study: NCT01619566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Study: NCT04053127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAVANS
Description: Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RAVANS
Description: Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
Study: NCT03364946

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational study
Study: NCT01439412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture and standard treatment
Description: This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment in general practice
Description: This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
Study: NCT01944111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plication
Description: Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
Study: NCT03071939

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers
Description: This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services).
Study: NCT02713412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 75g glucose and 150 mg of 13C-acetate made up to 300 ml with water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300ml water
Study: NCT05044559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Positive Air Way Group
Description: CPAP between 10 and 12 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days.
Study: NCT03555292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
Study: NCT02131350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photocoagulation
Description: Photocoagulation include focal/grid laser and/or panretinal photocoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT03308812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x
Description: Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x
Description: Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach
Description: Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
Study: NCT03519087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Evaluation for Nonarthritic Hip Disease
Description: The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture and Movement Training
Description: Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-of-choice
Description: Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
Study: NCT01577771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh
Study: NCT04412278

Intervention type: OTHER
Intervention: Online Survey
Description: Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
Study: NCT01727037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic intrabullous autologous blood instillation
Study: NCT03377101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Given IM
Study: NCT00733057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline as an add-on drug (200 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (200 mg/day)
Study: NCT00979849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled
Study: NCT00262847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study: NCT03377101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO
Study: NCT00262847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03377101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT03237507

Intervention type: DRUG
Intervention: S-1
Description: 40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
Study: NCT00262847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05831761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of analgesic efficacy protocol
Description: Comparison of 4 possible analgesic protocols
Study: NCT00262847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00871923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Erlotinib hydrochloride)
Description: 150 mg by mouth every day beginning Day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
Study: NCT05831761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of analgesic efficacy protocol
Description: Comparison of 4 possible analgesic protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of analgesic efficacy protocol
Description: Comparison of 4 possible analgesic protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of analgesic efficacy protocol
Description: Comparison of 4 possible analgesic protocols
Study: NCT03237507

Intervention type: DRUG
Intervention: oxaliplatin
Description: 100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
Study: NCT04077372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Guide (SICG)
Description: The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QOL) survey
Description: Quality of life survey by questionnaire (FACT-G) given every three months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) survey
Description: Quality of life survey by questionnaire (FACT-G) given every three months
Study: NCT03383757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpO2 Sensor application & blood draw
Description: At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
Study: NCT00583791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device closure with the AMPLATZER Muscular VSD Occluder
Description: Device: AMPLATZER Muscular VSD Occluder
Study: NCT02433873

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isomalto-oligosaccharide
Description: Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
Study: NCT04725760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort Vision Pro
Description: Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months.
Study: NCT02433873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomalto-oligosaccharide
Description: Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
Study: NCT03237507

Intervention type: DRUG
Intervention: oxaliplatin
Description: 100mg/m\^2 days 1，intravenous infusion, every 3 weeks.

Intervention type: DEVICE
Intervention: Hyperthermic Intraperitoneal
Description: hyperthermic intraperitoneal chemoperfusion

Intervention type: DRUG
Intervention: Paclitaxel
Description: intraperitoneal perfusion
Study: NCT02591147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride 38%
Description: Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group 2 (Placebo)
Description: Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
Study: NCT03907878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study: NCT03933215

Intervention type: DRUG
Intervention: Cladribine Tablets
Description: No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT00616512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GF Strong Water Protocol
Description: The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
Study: NCT03905616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging
Description: In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
Study: NCT04009707

Intervention type: OTHER
Intervention: MoCA (Montreal Cognitive Assessment) test
Description: the MoCA questionnaire is used to assess cognitive disorders

Intervention type: OTHER
Intervention: BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test
Description: This questionnaire is used to assess cognitive disorders
Study: NCT04554446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-MSAT(Motion style acupuncture treatment using traction)
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
Study: NCT00768300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan was administered orally once daily.